Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection

AIDS

Volumn 30, Issue 14, 2016, Pages 2195-2203

  Longenecker, Chris T ^a,b   Sattar, Abdus ^a   Gilkeson, Robert ^a,b   Mccomsey, Grace A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Carotid intima media thickness; Coronary artery calcium; HIV; Inflammation; Statin

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; CALCIUM; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; BLOOD; CAROTID ARTERY; CLINICAL TRIAL; COMPLICATION; CORONARY BLOOD VESSEL; DISEASE EXACERBATION; INTIMA; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CALCIUM; CAROTID ARTERIES; CHOLESTEROL, LDL; CORONARY VESSELS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 84969632526     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001167     Document Type: Article

References (37)

1. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015; 36:482-489.
2. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139-147.
3. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myo-cardial infarction. JAMA Intern Med 2013; 8:614-622.
4. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vi-jayakumar J, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
5. Ross AC, Rizk N, O'Riordan MA, Dogra V, El-Bejjani D, Storer N, et al. Relationship between inflammatory markers, endothe-lial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119-1127.
6. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-977.
7. Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 2013; 27:1263-1272.
8. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-1236.
9. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
10. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactiveprotein. N Engl J Med 2008; 359:2195-2207.
11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-1182.
12. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Use of atorvastatin in systemic lupus erythe-matosus in children and adolescents. Arthritis Rheum 2012; 64:285-296.
13. Ardoin SP, Schanberg LE, Sandborg CI, Barnhart HX, Evans GW, Yow E, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pub-ertal lupus patients with higher C reactive protein. Ann Rheum Dis 2014; 73:557-566.
14. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63:1571-1575.
15. Hermann F, Forster A, Chenevard R, Enseleit F, Hurlimann D, Corti R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005; 45:461-464.
16. Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Koniec-zynska M, Podolec P, et al. Influence of atorvastatin on cor-onary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011; 13:R117.
17. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011; 70:760-765.
18. Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012; 64:2836-2846.
19. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-595.
20. Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68:396-404.
21. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving anti-retroviral therapy. J Infect Dis 2014; 209:1156-1164.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
23. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
24. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21:93-111quiz 189-190.
25. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assess-ment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S49-73.
26. Regan S, Meigs J, Grinspoon S, Triant V, Mosepele M. Application of new ACC/AHA cholesterol guidelines to an HIV clinical care cohort. Seattle, WA: Conference on Retroviruses and Opportunistic Infections; 2015.
27. Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS 2014; 28:2061-2070.
28. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297:1344-1353.
29. Robinson AB, Tangpricha V, Yow E, Gurion R, Schanberg LE, McComsey GA, et al. Vitamin D status is a determinant of atorvastatin effect on carotid intima medial thickening progression rate in children with lupus: an Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) substudy. Lupus Sci Med 2014; 1:e000037.
30. Henein M, Granasen G, Wiklund U, Schmermund A, Guerci A, Erbel R, et al. High dose and long-term statin therapy accelerate coronary artery calcification. Int J Cardiol 2015; 184:581-586.
31. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002; 106:1077-1082.
32. Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 2014; 311:271-278.
33. Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, et al. Impact of statins on serial coronary calcification during ather-oma progression and regression. J Am Coll Cardiol 2015; 65:1273-1282.
34. Shaw LJ, Narula J, Chandrashekhar Y. The never-ending story on coronary calcium: is it predictive, punitive, or protective? J Am Coll Cardiol 2015; 65:1283-1285.
35. Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol 2016; 117:214-220.
36. Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015; 2:e52-e63.
37. Erlandson K, Jiang Y, Debanne S, McComsey G. Long-term changes in bone mineral density and insulin resistance on statins in HIV. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, 2015.